Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2020

View Archived Issues

Engineering better bacterial backstabbers

Targeting bystander protein improves sepsis outcome

Phase II study of Ad5-nCoV vaccine in healthy adults

Revive partners with Complete Phytochemical Solutions to develop psilocybin-based products

New spiroindoline derivatives show potential as remyelinating agents

PS-PLA1 as new therapeutic target in hyperthyroidism disorders

Chinese researchers patent RET inhibitors

Medshine Discovery presents new TRK inhibitors

Beijing Heli Consulting identifies polypeptide conjugates of odanacatib

Nanjing Gentai Pharmaceutical Technology identifies BTK inhibitors

Cancer drug delivery system targets tumor extracellular matrix, avoids healthy tissue

Roche describes new TLR antagonists

Ribonucleoside analogue EIDD-1931 is potently active against coronaviruses

New genetic variants in SLC34A2 gene tied to lung microlithiasis

Pemazyre approved in U.S. for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements

FDA clears anti-Claudin 18.2 antibody TST-001 to enter clinical trials for metastatic solid tumors

FDA approves Tukysa for advanced, unresectable or metastatic HER2-positive breast cancer

Initiation of phase III RUXCOVID trial of ruxolitinib for COVID-19-associated cytokine storm

Novartis plans phase III study of hydroxychloroquine in hospitalized patients with COVID-19 disease

Idorsia reports first pivotal results with daridorexant in insomnia

U.K. MHRA clears 4D Pharma to begin phase II study of MRx-4DP0004 in COVID-19

Ascendis reports fixed-dose TransCon PTH data from phase II PaTH Forward trial in hypoparathyroidism

Kazia updates findings from phase I study of Cantrixil in ovarian cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...